Diluted Russell viper-venom time improves identification of antiphospholipid syndrome in a lupus anticoagulant-positive patient population

Thrombosis and Haemostasis

Volumn 101, Issue 3, 2009, Pages 577-581

  Lambert, Marc ^a   Gisele, Ferrard Sasson ^a   Dubucquoi, Sylvain ^a   Hachulla, Eric ^a   Prin, Lionel ^a   Hatron, Pierre Yves ^a   Goudemand, Jenny ^a   Boffa, Marie Claire ^b   Caron, Claudine ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antiphospholipid autoantibodies; Diluted viper venom time

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DILUTED RUSSELL VIPER VENOM TIME; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; ROC CURVE; ROSNER INDEX; ROSOVE INDEX; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION TESTS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; ROC CURVE; VIPER VENOMS;

EID: 62549141826     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-06-0410     Document Type: Article

References (30)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
3. Petri M. Epidemiology of the antiphospholipid syndrome. J Autoimmun 2000; 15: 145-151.
4. Cervera R, Asherson RA. Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiol 2003; 207: 5-11.
5. Meroni PL. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. .1 Autoimmun 2008; 30: 99-103.
6. Galli M, Reber G, de Moerloose P, et al. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6:399-401.
7. Galli M, Luciani D, Bertolini G, et al. Anti-beta 2-glyeoprotein I, anriprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-2723.
8. Horbach DA, van Oort E, Donders RC, et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-924.
9. Wahl DG, Guillerain F, de Maistre E, et al. Metaanalysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7: 15-22.
10. Tubach F, Hayem G, Marchand JL, et al. IgG anti-beta2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 2000; 27: 1437-1443.
11. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.
12. Bas de I.aat H, Derksen RH, Urbanus RT, et al. β2-glyeoprolein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598-3602.
13. Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005; 3: 1160-1165.
14. Pengo V, Biasolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-1152.
15. Brandt JT Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
16. Pengo V, Biasiolo A, Rampazzo P, et al. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein 1 autoantibodies. Thromb Haemost 1999; 81: 256-258.
17. Galli M, Finazzi G, Norbis F, et al. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999; 81: 695-700.
18. Le Querrec A, Arnout J, Arnoux D, et al. Quantification of lupus anticoagulants in clinical samples using anti-β2GPl and anti-prolhrombin monoclonal antibodies. Thromb Haemost 2001, 86: 584-589.
19. Kandiah DA, Krilis SA. Anti-beta2-glycoprotein I and anti-prothrombin antibodies in patients with the 'antiphospholipid' syndrome: immunological specificity and clotting profiles. Lupus 1998; 7: 323-332.
20. Horbach DA, van Oort E, Derksen RH. et al. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity - discrimination between functional and non-functional anti-prothrombin-antibodies. Thromb Haemost 1998; 79: 790-795.
21. Goudernand J, Caron C, De Prost D, et al. Evaluation of sensitivity and specificity of a standardized procedure using different reagents for the detection of lupus anticoagulants. The Working Group on Hemosta-sis of the Sociélé Française de Biologic Clinique and for the Groupe d'Études sur I'Hemostase et la Thrombose. Thromb Haemost 1997; 77: 336-342.
22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
23. De Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies - from clinical association to pathologic mechanism. Nature Clinical Practice 2008; 4: 192-199.
24. Oosting JD, Derksen RH, Entjes HT, et al. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein 1. Thromb Haemost 1992; 67: 499-502.
25. McNeil HP, Simpson RJ. Chesterman CN, et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-1124.
26. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-536.
27. Matsuura E, Igarashi Y, Fujimoto M, et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-178.
28. Pengo V, Biasiolo A, Pegoraro C, et al. A two-step coagulation test to identify anti-β2-glyeoprotein I lupus anticoagulants. J Thromb Haemost 2004; 2: 702-707.
29. Forasterio R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to β2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231-1238.
30. Pengo Y A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 1048-1049.